Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Bioventus (NYSE:BVS - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $564.9 million.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Craig Hallum set a $15.00 target price on Bioventus and gave the stock a "buy" rating in a research report on Wednesday. Canaccord Genuity Group reissued a "buy" rating and set a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Performance

Shares of BVS traded down $0.10 during trading hours on Friday, hitting $6.70. The stock had a trading volume of 501,735 shares, compared to its average volume of 452,902. The firm has a market capitalization of $549.02 million, a PE ratio of -10.98 and a beta of 0.95. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus has a 12 month low of $5.25 and a 12 month high of $14.38. The stock has a fifty day moving average price of $8.40 and a 200 day moving average price of $10.10.

Insider Buying and Selling at Bioventus

In other Bioventus news, SVP Anthony D'adamio sold 4,380 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now owns 118,178 shares of the company's stock, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares in the company, valued at $1,210,745.23. This trade represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,208 shares of company stock worth $226,138 in the last three months. 32.90% of the stock is currently owned by company insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.